Impact of PrEP on Individuals, Health Care and Society

After the recent decision allowing pre-exposure prophylaxis (PrEP) to be prescribed for HIV prevention within the National Health Service, what are the potential implications for individuals, healthcare, and society?

Introduction:

Pre-exposure prophylaxis (PrEP) refers to the administration of medication to individuals who have not been diagnosed with HIV, aiming to lower the risk of contracting the virus (Spinner et al., 2016). Typically, PrEP involves a combination pill of antiretrovirals, such as tenofovir disoproxil fumarate and emtricitabine (Brydon, 2018). While these antiretrovirals are used to treat HIV-infected individuals, providing lifelong therapy to manage the infection and reduce the viral load, PrEP serves a preventive purpose in HIV-negative individuals. It works by reducing viral replication to a level that allows the immune system to eliminate infected cells, thus preventing the establishment of HIV infection (Brydon, 2018).

Extensive evidence supports the use of PrEP, especially in high-risk populations like men who have sex with men (MSM), leading to its approval for HIV prevention within the National Health Service (NHS) and Scotland (Nandwani, 2017). The following sections will explore the potential impact of this approval on individuals, healthcare, and society.

Note: We avoid AI-generated writing at all cost.

Individuals:

The availability of NHS-funded PrEP is expected to have significant effects on individuals. By securing funding for PrEP, the NHS can improve access to and affordability of these drugs, particularly benefiting vulnerable and socioeconomically disadvantaged individuals who are at higher risk of HIV infection (Spinner et al., 2016).

One of the key individual advantages of PrEP availability is the expansion of options for those at risk of HIV. Current preventive strategies, like condom use, may have limitations in practical application due to various factors, including perceptions of reduced sexual pleasure (Dolling et al., 2014). PrEP provides an alternative to condom use, empowering individuals to manage their health risks effectively (Frankis et al., 2016). Additionally, PrEP may appeal to individuals who face cultural, religious, or personal barriers to traditional HIV prevention practices, thus broadening access to preventive measures and promoting healthier sexual behaviors (Stewart, 2016).

However, it is important to communicate that PrEP does not protect against sexually transmitted infections (STIs), and condom use remains crucial for preventing both HIV and STIs (Storholm et al., 2017). Moreover, PrEP’s individual benefits rely on optimal adherence to the medication; non-adherence reduces its effectiveness and increases the risk of HIV transmission (Storholm et al., 2017). Careful selection of the target population and individual education on PrEP use will be essential to ensure its benefits are realized (NHS England, 2018).

Healthcare:

From a healthcare perspective, NHS funding for PrEP can have several positive outcomes. PrEP has shown to significantly reduce HIV transmission rates in trials and real-world evaluations, potentially leading to a reduced HIV burden in the population and better management of population health (Fonner et al., 2016; McCormack et al., 2016; Sagaon-Teyssier et al., 2016).

A significant impact of PrEP on healthcare is the potential for cost savings in the short and long term due to reduced rates of HIV infection. Cost-effectiveness and modeling analyses have demonstrated that PrEP use in MSM can lead to savings, depending on various factors such as condom use rates, STI rates, and drug costs (Cambiano et al., 2018; Fu et al., 2018).

However, concerns have been raised regarding potential negative effects of PrEP, including a possible decline in condom use and an increase in STIs, leading to additional healthcare costs (Kelen and Cresswell, 2017). Monitoring and managing such risks will be crucial to ensuring the cost-effectiveness of PrEP implementation (Cambiano et al., 2018).

Society:

On a societal level, it is essential to consider the broader ethical, social, and cultural aspects of PrEP use. HIV is often associated with stigma, and any measures to combat infection rates and reduce risks in relationships between HIV-negative and HIV-positive individuals may help reduce this stigma to some extent (Grace et al., 2018). Alleviating stigma can significantly improve the quality of life and well-being of affected individuals (Grace et al., 2018).

However, societal views on HIV management can be polarized, and negative connotations might be associated with PrEP use, potentially leading to concerns about increased promiscuity or condomless sex (Knight et al., 2016; Brydon, 2018). Ensuring public awareness, accurate information, and education about PrEP’s benefits are essential to counter misinformation and unfounded claims in the media (Jaspal and Nerlich, 2017).

In conclusion, the approval of PrEP for HIV prevention within the NHS is supported by a robust evidence base. Its potential impact extends to individuals, healthcare, and society at large, with benefits including reduced HIV infections, cost savings, improved access to health services, and a potential reduction in HIV-related stigma. To maximize the positive outcomes, careful monitoring and education efforts are needed to ensure safe and effective PrEP implementation.